CN100528151C - 莫达非尼药物剂型 - Google Patents

莫达非尼药物剂型 Download PDF

Info

Publication number
CN100528151C
CN100528151C CNB03821749XA CN03821749A CN100528151C CN 100528151 C CN100528151 C CN 100528151C CN B03821749X A CNB03821749X A CN B03821749XA CN 03821749 A CN03821749 A CN 03821749A CN 100528151 C CN100528151 C CN 100528151C
Authority
CN
China
Prior art keywords
modafinil
unit dose
solid
basically
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB03821749XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1681486A (zh
Inventor
克雷格·希科克
阿尔帕·帕里克
皮约什·R·帕特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32511269&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100528151(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon LLC filed Critical Cephalon LLC
Publication of CN1681486A publication Critical patent/CN1681486A/zh
Application granted granted Critical
Publication of CN100528151C publication Critical patent/CN100528151C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNB03821749XA 2002-09-13 2003-09-12 莫达非尼药物剂型 Expired - Fee Related CN100528151C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41039502P 2002-09-13 2002-09-13
US60/410,395 2002-09-13
US10/660,058 2003-09-11
US10/660,058 US20040116532A1 (en) 2002-09-13 2003-09-11 Pharmaceutical formulations of modafinil

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2009101522991A Division CN101606916B (zh) 2002-09-13 2003-09-12 莫达非尼片剂及其应用

Publications (2)

Publication Number Publication Date
CN1681486A CN1681486A (zh) 2005-10-12
CN100528151C true CN100528151C (zh) 2009-08-19

Family

ID=32511269

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB03821749XA Expired - Fee Related CN100528151C (zh) 2002-09-13 2003-09-12 莫达非尼药物剂型

Country Status (21)

Country Link
US (4) US20040116532A1 (enExample)
EP (1) EP1539126B1 (enExample)
JP (1) JP5039246B2 (enExample)
KR (1) KR101125462B1 (enExample)
CN (1) CN100528151C (enExample)
AU (1) AU2003267156B2 (enExample)
BR (1) BR0314514A (enExample)
CA (1) CA2498260C (enExample)
DK (1) DK1539126T3 (enExample)
EA (1) EA012964B1 (enExample)
ES (1) ES2392580T3 (enExample)
IL (1) IL167054A (enExample)
IS (1) IS2871B (enExample)
MX (1) MXPA05002827A (enExample)
NO (1) NO333614B1 (enExample)
NZ (1) NZ538941A (enExample)
PL (1) PL375833A1 (enExample)
PT (1) PT1539126E (enExample)
SI (1) SI1539126T1 (enExample)
TW (1) TWI335217B (enExample)
WO (1) WO2004024134A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416792C (en) 2000-07-27 2010-02-09 Teva Pharmaceutical Industries Ltd. Crystalline and pure modafinil, and process of preparing the same
US20080058424A1 (en) * 2002-05-23 2008-03-06 Cephalon, Inc. Novel pharmaceutical formulations of modafinil
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
US20040116532A1 (en) 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
WO2004082624A2 (en) * 2003-03-17 2004-09-30 Neurohealing Pharmaceuticals, Inc. Modafinil-based neurorehabilitation of impaired neurological function associated with injury
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
US8153159B2 (en) * 2003-09-18 2012-04-10 Cephalon, Inc. Modafinil modified release pharmaceutical compositions
CN101031290B (zh) * 2003-09-18 2011-09-21 赛福伦公司 改良释放的莫达非尼药物组合物
WO2005099822A2 (en) * 2004-04-13 2005-10-27 Cephalon, Inc. Reduction of drug / drug interactions with modafinil
EP1740181A1 (en) * 2004-04-22 2007-01-10 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders ii
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
US20060024370A1 (en) 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
EP1789048A1 (en) * 2004-09-03 2007-05-30 Boehringer Ingelheim International GmbH Method for the treatment of attention deficit hyperactivity disorder
BRPI0500520A (pt) * 2005-02-16 2006-09-26 Henry Jun Suzuki uso de agentes flavorizantes aromáticos de alto ponto de fusão como agentes solubilizantes ou inibidores de cristalização em composições farmacêuticas
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
JP2008531714A (ja) * 2005-03-04 2008-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 不安障害の治療用及び／又は予防用の医薬組成物
CA2599721A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
CA2608249A1 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Method for the treatment of drug abuse with flibanserin
JP2008540673A (ja) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬剤誘発性性機能不全の治療方法
CA2608713A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of sexual dysfunctions due to medical conditions
EP1912650B8 (en) 2005-08-03 2017-10-18 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
EP1945214A1 (en) * 2005-10-29 2008-07-23 Boehringer Ingelheim International GmbH Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
CA2641917A1 (en) * 2006-02-18 2007-08-23 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin
JP2009541443A (ja) 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 尿失禁及び関連疾患の治療のためのフリバンセリン
US20090318469A1 (en) * 2006-07-14 2009-12-24 Boehringer Ingelheim International Gmbh Use of Flibanserin for the Treatment of Sexual Disorders in Females
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
KR20090042967A (ko) * 2006-08-14 2009-05-04 베링거 인겔하임 인터내셔날 게엠베하 플리반세린 제형 및 이의 제조방법
CN104721168A (zh) * 2006-08-25 2015-06-24 贝林格尔·英格海姆国际有限公司 控制释放系统及其制造方法
US8173169B2 (en) * 2007-07-11 2012-05-08 Hikma Pharmaceuticals Formulation and process for the preparation of modafinil
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
FR2987265B1 (fr) * 2012-02-28 2014-02-28 Debregeas Et Associes Pharma Composition pharmaceutique sous forme de sirop a base de modafinil, son procede de fabrication et son application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1249932A (zh) * 1999-09-29 2000-04-12 付俊昌 一种莫达芬尼及其光学对映体l及d异构体的新用途
US6346548B1 (en) * 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1570994A (en) 1923-11-20 1926-01-26 William A Cook Spring-forming die
US3629393A (en) 1969-09-11 1971-12-21 Nikken Chemicals Co Ltd Release-sustaining-tablet
GB1584462A (en) * 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
DE2927988A1 (de) 1979-07-11 1981-02-05 Thomae Gmbh Dr K Neue 8-phenyl-purine, deren herstellung und deren verwendung als arzneimittel
US4431645A (en) 1982-03-08 1984-02-14 Schering Corporation Antihypertensive agents
HU187215B (en) 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
US4584285A (en) 1983-06-02 1986-04-22 Schering Corporation Antihypertensive agents
US4710519A (en) 1985-09-30 1987-12-01 Basf Corporation Process for preparing spray dried acetaminophen powder and the powder prepared thereby
FR2593809B1 (fr) * 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
US5084277A (en) 1988-08-30 1992-01-28 Greco John C Vaginal progesterone tablet
FR2663225B1 (fr) * 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
FR2684875B1 (fr) * 1991-12-13 1995-05-24 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique.
FR2697162B1 (fr) * 1992-10-23 1995-01-13 Lafon Labor Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux.
GB9225492D0 (en) 1992-12-05 1993-01-27 Glaxo Group Ltd Amine derivatives
TW272942B (enExample) 1993-02-10 1996-03-21 Takeda Pharm Industry Co Ltd
US5843347A (en) * 1993-03-23 1998-12-01 Laboratoire L. Lafon Extrusion and freeze-drying method for preparing particles containing an active ingredient
FR2702968B1 (fr) 1993-03-23 1995-06-23 Lafon Labor Procédé de préparation de particules renfermant un ingrédient actif par extrusion et lyophilisation .
FR2706767B1 (enExample) * 1993-06-22 1995-09-08 Lafon Labor
FR2707637B1 (fr) * 1993-06-30 1995-10-06 Lafon Labor Nouveaux dérivés d'acétamide, leur procédé de préparation et leur utilisation en thérapeutique.
US5506248A (en) 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
SI9500173B (sl) 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
WO1997025989A1 (en) * 1996-01-19 1997-07-24 Glaxo Group Limited Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
JPH09208468A (ja) * 1996-02-02 1997-08-12 Dainippon Pharmaceut Co Ltd ｐ−クロロ−Ｎ−（２−モルホリノエチル）ベンズアミドを含有する錠剤
US5948437A (en) 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
EP2277517A1 (en) 1996-11-15 2011-01-26 Ajinomoto Co., Inc. Nateglinide tablet composition
GB9714274D0 (en) 1997-07-08 1997-09-10 Zeneca Ltd Pharmaceutical composition
CA2301883A1 (en) 1997-09-11 1999-03-18 Nycomed Danmark A/S Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (nsaids)
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
HUP0105463A3 (en) 1998-12-18 2003-03-28 Abbott Lab Controlled release formulation of divalproex sodium
HUP0104606A3 (en) * 1998-12-18 2003-01-28 Basf Ag A pharmaceutical mixture comprising a profen
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6455588B1 (en) * 1999-08-20 2002-09-24 Cephalon, Inc. Compositions including modafinil for treatment of eating disorders and for appetite stimulation
US6204245B1 (en) 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
FR2804322B1 (fr) * 2000-01-31 2002-04-19 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament destine a corriger les troubles de la vigilance associes aux myopathies
US20010034373A1 (en) 2000-02-09 2001-10-25 Matthew Miller Low dose modafinil for enhancement of cognitive function
US6670358B2 (en) 2000-05-16 2003-12-30 Cephalon, Inc. Substituted thioacetamides
US6492396B2 (en) 2000-05-16 2002-12-10 Cephalon, Inc. Substituted thioacetamides
BR0114814A (pt) * 2000-10-11 2005-01-25 Cephalon Inc Composições compreendendo composto de modafinila e seu uso
US6489363B2 (en) * 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US6919378B2 (en) * 2000-10-11 2005-07-19 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
KR100911952B1 (ko) 2000-10-11 2009-08-13 세파론, 인코포레이티드 모다피닐 화합물을 포함하는 조성물
US7141555B2 (en) 2000-12-19 2006-11-28 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
ES2281527T3 (es) 2001-05-25 2007-10-01 Cephalon, Inc. Formulaciones farmaceuticas solidas que comprenden modafinilo.
US7576133B2 (en) * 2002-03-11 2009-08-18 Carl Henry Lawyer Methods and compositions for nasal administration of modafinil
US7229644B2 (en) 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
WO2004004692A1 (en) 2002-07-08 2004-01-15 Ranbaxy Laboratories Limited Processes for the preparation of oral dosage formulations of modafinil
WO2004010979A1 (en) 2002-07-25 2004-02-05 Ranbaxy Laboratories Limited Processes for the preparation of oral dosage formulations of modafinil
US20040116532A1 (en) * 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346548B1 (en) * 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
CN1249932A (zh) * 1999-09-29 2000-04-12 付俊昌 一种莫达芬尼及其光学对映体l及d异构体的新用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
a douboe-blind placebo-controlled,ascending-doseevaluationof the pharmacokinetics and tolerability of modafiniltablets inhealthy male volunteers. wong Y nancy et al.JOURNAL OF CLINICAL PHARMACOLOGY,Vol.39 No.1. 1999 *

Also Published As

Publication number Publication date
JP5039246B2 (ja) 2012-10-03
JP2006522006A (ja) 2006-09-28
ES2392580T3 (es) 2012-12-12
MXPA05002827A (es) 2005-08-16
US20120322880A1 (en) 2012-12-20
IS2871B (is) 2014-03-15
CN1681486A (zh) 2005-10-12
US8686047B2 (en) 2014-04-01
SI1539126T1 (sl) 2012-11-30
PL375833A1 (en) 2005-12-12
PT1539126E (pt) 2012-11-14
EA012964B1 (ru) 2010-02-26
HK1076734A1 (en) 2006-01-27
NO20051079L (no) 2005-03-23
US20080207761A1 (en) 2008-08-28
WO2004024134A1 (en) 2004-03-25
KR20050113163A (ko) 2005-12-01
KR101125462B1 (ko) 2012-03-28
US20120316244A1 (en) 2012-12-13
WO2004024134A8 (en) 2005-07-21
US20040116532A1 (en) 2004-06-17
EA200500488A1 (ru) 2005-12-29
TW200412934A (en) 2004-08-01
US8268892B2 (en) 2012-09-18
CA2498260A1 (en) 2004-03-25
NZ538941A (en) 2007-09-28
AU2003267156B2 (en) 2010-03-11
BR0314514A (pt) 2005-08-09
AU2003267156A1 (en) 2004-04-30
IS7714A (is) 2005-02-24
TWI335217B (en) 2011-01-01
EP1539126A1 (en) 2005-06-15
NO333614B1 (no) 2013-07-22
DK1539126T3 (da) 2012-11-19
CA2498260C (en) 2014-02-04
US8859621B2 (en) 2014-10-14
EP1539126B1 (en) 2012-08-29
IL167054A (en) 2011-07-31

Similar Documents

Publication Publication Date Title
CN100528151C (zh) 莫达非尼药物剂型
DE602004007225T2 (de) Methode zur behandlung von erkrankungen der unteren harnwege
KR20200016889A (ko) 과다 졸림증을 치료하기 위한 방법 및 조성물
EP0220696A2 (en) Use of buspirone for preparing pharmaceutical compositions for alleviation of phobic anxiety
CN100563660C (zh) 用于正常化睡眠/觉醒周期的化合物
WO2023278824A1 (en) Methods for treating depressive states
MX2008000249A (es) Combinaciones de eszopiclona y o-desmetilvenlafaxina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y cognitivos.
US11744833B2 (en) Pharmaceutical compositions and methods for treatment of insomnia
US6008222A (en) Method for oral administration of buspirone and nefazodone
US20050256131A1 (en) Pharmaceutical active substance combination and the use thereof
JP2001510800A (ja) 注意欠損／活動亢進症の治療のためのアルカノイルカルニチン誘導体の使用
WO2023158424A1 (en) Novel pharmaceutical compositions and methods for treatment of insomnia
CN101606916B (zh) 莫达非尼片剂及其应用
NZ249041A (en) Use of brofaromine(4-(7-bromo-5-methoxy-2-benzofuranyl)-piperdine) for treating post-traumatic stress disorder
ULC PrMYLAN-SERTRALINE
ULC PR SERTRALINE
Dom-SERTRALINE et al. DOMINION PHARMACAL
Tablets et al. Pr MYLAN-CITALOPRAM
Tablets et al. PrQ-CITALOPRAM
HK1076734B (en) Tablets containing 250 to 450 mg of modafinil
WO1993016696A1 (en) Brofaromine as an agent for treating social phobia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090819

Termination date: 20150912

EXPY Termination of patent right or utility model